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1268metabolism products, particularly tetracosapentae-
noic acid (24:5n-3) and tetracosahexaenoic acid
(24:6n-3), were increased in atrial, but not in ven-
tricular myocardium after intrapericardial HUFA
administration, which was associated with a higher
ventricular potential to ﬁnalize DHA synthesis.
Tetracosahexaenoic acid requires carnitine octanoyl-
transferase, a family member of carnitine acetyl-
transferases, for transportation into the endoplasmic
reticulum to undergo ﬁnal beta-oxidation. It was
previously shown that carnitine palmitoyltransferase
(1b and 2) is reduced in atrial compared with ven-
tricular myocardium. It is proposed to evaluate beta-
oxidation as a novel target for endogenous HUFA
concentrations. In accordance with the report by
Nigam et al. (1), no changes of HUFA levels were
found after a challenge with the proinﬂammatory
peroxisome proliferator-activated receptor-alpha
agonist fenoﬁbrate or in a talcum-induced pericar-
ditis model.
Up to now, involvement of cardiac load conditions
and the differential endogenous HUFA metabolism
were not sufﬁciently taken into account, which may
provide a rationale for divergent ﬁndings of HUFA
treatment in previous trials.Tobias Glück, MD
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Analysis to Data of
Previously Published
Chronic Heart Failure TrialsI enjoyed studying the contribution by Ahmad et al.
(1), and the accompanying editorial by Francis et al.
(2), published in the October 28, 2014 issue of the
Journal, about the application of cluster analysis to
the data from 1,619 participants of HF-ACTION (Heart
Failure: A Controlled Trial Investigating Outcomes of
Exercise Training) study. The investigators reported
that cluster analysis provided an advantage over
traditional phenotyping, based on the subjective
symptomatic assessment of the patients via the New
York Heart Association functional classiﬁcation I
to IV, and A to D stages, and imaging-based left
ventricular ejection fraction (LVEF) in predicting
outcomes (all-cause and cardiovascular, mortality,
and hospitalization risks) and response to surrogate
parameters (change in peak oxygen consumption and
in standard 6-min walk test). Clinicians following
longitudinally large numbers of heart failure (HF)
patients with a reduced LVEF in cardiology clinics
have long been accustomed to the incongruity be-
tween the functional classiﬁcation/staging (New York
Heart Association class II to IV) and LVEF (#35%) and
outcomes of their patients, stemming from our cur-
rent coarse phenotyping of a highly heterogeneous
disease as HF and the impact of comorbidities.
Ahmad et al. (1) arbitrarily employed 45 pre-
speciﬁed clinical variables and identiﬁed 4 pheno-
typic clusters, with intracluster similarities and
intercluster differences, in which they showed
diverse mortality and hospitalization rates. It is of
interest that in the exhaustive list of variables used
(1), a measure of the patients’ overall compliance with
their management in general, and with drug taking in
particular, is missing (issues of frequent concern in
cardiology clinics), for which the investigators are not
responsible. Ahmed et al. (1) and Francis et al. (2)
cited the reasons why a number of trials (refs. 7, 8,
and 35 in Ahmed et al. [1]) and patients with HF with a
reduced LVEF (refs. 5 to 8 in Francis et al. [2]) “have
failed to meet their endpoints” (2), and Ahmed et al.
(1) stated that “we have seen such little progress in
developing new treatments for this disorder.”
Although we need to adopt the philosophy of
enhanced and reﬁned phenotyping in designing
future HF clinical trials (2), what should have
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1269precedence now are the following objectives: 1) a
“culture” change in practice and research, conducive
to distancing ourselves from the attachment and the
“false security” provided by the New York Heart
Association functional classiﬁcation I to IV, A to D
staging and LVEF, when phenotyping our HF
patients, and adopting more liberal classiﬁcation
schemes; and 2) application in research of cluster
analysis to existing data from previously published
randomized HF clinical trials, and data from elec-
tronic medical records, modeled after the present
study (1), in an attempt to come up with winning sets
of a few clusters that will outperform our current HF
classiﬁcation systems. These 2 objectives will pave
the way to a future when design of “rational” clinical
trials (2) will be feasible and cost-effective.*John E. Madias, MD
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Clinical Phenotypes of
Heart Failure SyndromeThe paper by Ahmad et al. (1) used cluster analysis to
describe clinical phenotypes in chronic heart failure
(HF) and identiﬁed 4 “phenotypically distinct and
clinically meaningful groups.” Their cluster analysis
was based on 45 clinical variables and therapeutic
effects from 1,619 patients of the HF-ACTION (Heart
Failure: A Controlled Trial Investigating Outcomes
of Exercise Training) study (2), which evaluated
the effect of exercise training on morbidity and
mortality in patients with chronic systolic HF.
Ahmad et al. (1) named the patient clusters “chronic
heart failure phenotypes” and emphasized “the
high degree of disease heterogeneity” and the
necessity for more precise phenotyping of the HF
syndrome.In our opinion, the cluster analysis of 45 variables
and their grouping in 4 phenotypes is unjustiﬁed
from a pathophysiological point of view. It is rather a
random collection of clinical characteristics with
many of those having a variable degree of life-
threatening signiﬁcance. In contrast to the preced-
ing classiﬁcation, a robust clinical phenotype should
have characteristics that could easily identify an en-
tity with well-deﬁned pathophysiology. The classiﬁ-
cation of the clinical forms of HF in discrete
categories (phenotypes) should recognize the basic
disease process in order to apply the appropriate
treatment. In general, the deﬁnition of a cluster
suggests that there is an internal “togetherness” of
the different clinical characteristics, but the deﬁni-
tion does not imply that 2 particular characteristics in
the same cluster obligatorily have much in common
(3). In reality, the mentioned cardiac symptoms,
signs, and biological elements are nodes with some
associative memory in a vast network of clinical
connections, but they do not form a genuine pheno-
type with discrete pathophysiology.
To explain the molecular, physiological, and
pathological alterations of HF, we should shift
attention to the integrated methodology of systems
biology approach. The nature of the HF syndrome is
characterized by a progressive clinical deterioration
that is explained better with further integration
of data from the ﬁelds of modeling, “omics,” and
complex networks. A new conceptual paradigm of
HF progression needs the construction of novel
models (phenotypes) and clinical networks (clus-
ters) that include the characteristic emergent prop-
erties (signs, symptoms, and biological markers) of
the HF syndrome (4). The human HF syndrome is a
complex entity of mechanistic nature that is inter-
related with 2 adaptive functional regulatory sys-
tems, the remodeling left ventricular procedure
and the homeostatic neurohumoral systems. The
activation of the self-organized positive feedback
stabilization mechanisms of the renin-angiotensin-
aldosterone system, the adrenergic system, and
the natriuretic peptide axis system are important
to strengthen or suppress the cardiac remodeling
procedure.
Francis et al. (5), in an editorial comment regarding
the paper of Ahmad et al. (1), stress the importance of
“pairing phenotypes identiﬁed with cluster analyses
with an ‘omics’ approach.” This is correct, but for
clinical and therapeutic reasons it seems more im-
portant for there to be a meaningful physiolog-
ical relationship between the various components
of “clusters.” With a systems biology approach,
the pathophysiological “interconnection” of the
